Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C21H25N.ClH |
| Molecular Weight | 327.891 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN(C\C=C/C#CC(C)(C)C)CC1=C2C=CC=CC2=CC=C1
InChI
InChIKey=BWMISRWJRUSYEX-UYTGOYFPSA-N
InChI=1S/C21H25N.ClH/c1-21(2,3)15-8-5-9-16-22(4)17-19-13-10-12-18-11-6-7-14-20(18)19;/h5-7,9-14H,16-17H2,1-4H3;1H/b9-5-;
Terbinafine (brand name Lamisil, Terbisil, Terboderm and others) is an antifungal medication used to treat ringworm and fungal nail infections. Terbinafine inhibits ergosterol synthesis by inhibiting squalene epoxidase, an enzyme that is part of the fungal cell membrane synthesis pathway. Because terbinafine prevents the conversion of squalene to lanosterol, ergosterol cannot be synthesized. This is thought to change cell membrane permeability, causing fungal cell lysis. Many side effects and adverse drug reactions have been reported with oral terbinafine hydrochloride possibly due to its extensive biodistribution and the often extended durations involved in antifungal treatment (longer than two months).
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1888 |
30.0 nM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | LAMISIL Approved UseUses cures most athlete’s foot (tinea pedis) between the toes.Effectiveness on the bottom or sides of foot is unknown. cures most jock itch (tinea cruris) and ringworm (tinea corporis) relieves itching, burning, cracking and scaling which accompany these conditions Launch Date1998 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8593011/ |
250 mg 1 times / day multiple, oral dose: 250 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TERBINAFINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.34 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8593011/ |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
TERBINAFINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1 μg/mL |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
TERBINAFINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
10.48 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8593011/ |
250 mg 1 times / day multiple, oral dose: 250 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TERBINAFINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4.74 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8593011/ |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
TERBINAFINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4.56 μg × h/mL |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
TERBINAFINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
16.5 day EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8593011/ |
250 mg 1 times / day multiple, oral dose: 250 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TERBINAFINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
36 h |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
TERBINAFINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1% |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
TERBINAFINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
500 mg 2 times / day multiple, oral Highest studied dose Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Sources: Page: p.155 |
unhealthy, 31 n = 27 Health Status: unhealthy Condition: Eumycetoma Age Group: 31 Sex: M+F Population Size: 27 Sources: Page: p.155 |
Disc. AE: Neutropenia, Neutropenia... AEs leading to discontinuation/dose reduction: Neutropenia (7.4%) Sources: Page: p.155Neutropenia (3.7%) Glutamic-oxaloacetic transaminase increased (3.7%) Serum glutamic-pyruvic transaminase increased (3.7%) |
5 g single, oral Overdose Dose: 5 g Route: oral Route: single Dose: 5 g Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Fingernail onychomycosis|Toenail onychomycosis Sources: Page: p.6 |
Other AEs: Nausea, Vomiting... Other AEs: Nausea Sources: Page: p.6Vomiting Abdominal pain Dizziness Rash Urination frequency of Headache |
1 % 1 times / day multiple, topical Recommended Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: Page: p.8 |
unhealthy Health Status: unhealthy Condition: Tinea|tinea pedis|tinea corporis|tinea cruris Sources: Page: p.8 |
|
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: p.3 |
unhealthy n = 465 Health Status: unhealthy Condition: Fingernail onychomycosis|Toenail onychomycosis Population Size: 465 Sources: Page: p.3 |
Disc. AE: Headache... AEs leading to discontinuation/dose reduction: Headache (0.2%) Sources: Page: p.3 |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: p.4 |
unhealthy n = 465 Health Status: unhealthy Condition: Fingernail onychomycosis|Toenail onychomycosis Population Size: 465 Sources: Page: p.4 |
Disc. AE: Diarrhea, Dyspepsia... AEs leading to discontinuation/dose reduction: Diarrhea (0.6%) Sources: Page: p.4Dyspepsia (0.4%) Abdominal pain (0.4%) Nausea (0.2%) Rash (0.9%) Pruritus (0.2%) Liver enzyme abnormal (0.2%) Taste disturbance (0.2%) Visual disturbance (0.9%) |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Fingernail onychomycosis|Toenail onychomycosis Sources: Page: p.1 |
Disc. AE: Liver failure, Taste disturbance... AEs leading to discontinuation/dose reduction: Liver failure Sources: Page: p.1Taste disturbance (severe) Smell alteration Depressive symptom Neutropenia (severe) Stevens-Johnson syndrome Toxic epidermal necrolysis Erythema multiforme Exfoliative dermatitis Bullous dermatitis Drug reaction with eosinophilia and systemic symptoms |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: p.3 |
unhealthy Health Status: unhealthy Condition: Fingernail onychomycosis|Toenail onychomycosis Sources: Page: p.3 |
Disc. AE: Lupus erythematosus, Thrombotic microangiopathy... AEs leading to discontinuation/dose reduction: Lupus erythematosus Sources: Page: p.3Thrombotic microangiopathy Thrombotic thrombocytopenic purpura Hemolytic uremic syndrome |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Glutamic-oxaloacetic transaminase increased | 3.7% Disc. AE |
500 mg 2 times / day multiple, oral Highest studied dose Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Sources: Page: p.155 |
unhealthy, 31 n = 27 Health Status: unhealthy Condition: Eumycetoma Age Group: 31 Sex: M+F Population Size: 27 Sources: Page: p.155 |
| Neutropenia | 3.7% Disc. AE |
500 mg 2 times / day multiple, oral Highest studied dose Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Sources: Page: p.155 |
unhealthy, 31 n = 27 Health Status: unhealthy Condition: Eumycetoma Age Group: 31 Sex: M+F Population Size: 27 Sources: Page: p.155 |
| Serum glutamic-pyruvic transaminase increased | 3.7% Disc. AE |
500 mg 2 times / day multiple, oral Highest studied dose Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Sources: Page: p.155 |
unhealthy, 31 n = 27 Health Status: unhealthy Condition: Eumycetoma Age Group: 31 Sex: M+F Population Size: 27 Sources: Page: p.155 |
| Neutropenia | 7.4% Disc. AE |
500 mg 2 times / day multiple, oral Highest studied dose Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Sources: Page: p.155 |
unhealthy, 31 n = 27 Health Status: unhealthy Condition: Eumycetoma Age Group: 31 Sex: M+F Population Size: 27 Sources: Page: p.155 |
| Abdominal pain | 5 g single, oral Overdose Dose: 5 g Route: oral Route: single Dose: 5 g Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Fingernail onychomycosis|Toenail onychomycosis Sources: Page: p.6 |
|
| Dizziness | 5 g single, oral Overdose Dose: 5 g Route: oral Route: single Dose: 5 g Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Fingernail onychomycosis|Toenail onychomycosis Sources: Page: p.6 |
|
| Headache | 5 g single, oral Overdose Dose: 5 g Route: oral Route: single Dose: 5 g Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Fingernail onychomycosis|Toenail onychomycosis Sources: Page: p.6 |
|
| Nausea | 5 g single, oral Overdose Dose: 5 g Route: oral Route: single Dose: 5 g Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Fingernail onychomycosis|Toenail onychomycosis Sources: Page: p.6 |
|
| Rash | 5 g single, oral Overdose Dose: 5 g Route: oral Route: single Dose: 5 g Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Fingernail onychomycosis|Toenail onychomycosis Sources: Page: p.6 |
|
| Urination frequency of | 5 g single, oral Overdose Dose: 5 g Route: oral Route: single Dose: 5 g Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Fingernail onychomycosis|Toenail onychomycosis Sources: Page: p.6 |
|
| Vomiting | 5 g single, oral Overdose Dose: 5 g Route: oral Route: single Dose: 5 g Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Fingernail onychomycosis|Toenail onychomycosis Sources: Page: p.6 |
|
| Headache | 0.2% Disc. AE |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: p.3 |
unhealthy n = 465 Health Status: unhealthy Condition: Fingernail onychomycosis|Toenail onychomycosis Population Size: 465 Sources: Page: p.3 |
| Liver enzyme abnormal | 0.2% Disc. AE |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: p.4 |
unhealthy n = 465 Health Status: unhealthy Condition: Fingernail onychomycosis|Toenail onychomycosis Population Size: 465 Sources: Page: p.4 |
| Nausea | 0.2% Disc. AE |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: p.4 |
unhealthy n = 465 Health Status: unhealthy Condition: Fingernail onychomycosis|Toenail onychomycosis Population Size: 465 Sources: Page: p.4 |
| Pruritus | 0.2% Disc. AE |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: p.4 |
unhealthy n = 465 Health Status: unhealthy Condition: Fingernail onychomycosis|Toenail onychomycosis Population Size: 465 Sources: Page: p.4 |
| Taste disturbance | 0.2% Disc. AE |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: p.4 |
unhealthy n = 465 Health Status: unhealthy Condition: Fingernail onychomycosis|Toenail onychomycosis Population Size: 465 Sources: Page: p.4 |
| Abdominal pain | 0.4% Disc. AE |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: p.4 |
unhealthy n = 465 Health Status: unhealthy Condition: Fingernail onychomycosis|Toenail onychomycosis Population Size: 465 Sources: Page: p.4 |
| Dyspepsia | 0.4% Disc. AE |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: p.4 |
unhealthy n = 465 Health Status: unhealthy Condition: Fingernail onychomycosis|Toenail onychomycosis Population Size: 465 Sources: Page: p.4 |
| Diarrhea | 0.6% Disc. AE |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: p.4 |
unhealthy n = 465 Health Status: unhealthy Condition: Fingernail onychomycosis|Toenail onychomycosis Population Size: 465 Sources: Page: p.4 |
| Rash | 0.9% Disc. AE |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: p.4 |
unhealthy n = 465 Health Status: unhealthy Condition: Fingernail onychomycosis|Toenail onychomycosis Population Size: 465 Sources: Page: p.4 |
| Visual disturbance | 0.9% Disc. AE |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: p.4 |
unhealthy n = 465 Health Status: unhealthy Condition: Fingernail onychomycosis|Toenail onychomycosis Population Size: 465 Sources: Page: p.4 |
| Bullous dermatitis | Disc. AE | 250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Fingernail onychomycosis|Toenail onychomycosis Sources: Page: p.1 |
| Depressive symptom | Disc. AE | 250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Fingernail onychomycosis|Toenail onychomycosis Sources: Page: p.1 |
| Drug reaction with eosinophilia and systemic symptoms | Disc. AE | 250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Fingernail onychomycosis|Toenail onychomycosis Sources: Page: p.1 |
| Erythema multiforme | Disc. AE | 250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Fingernail onychomycosis|Toenail onychomycosis Sources: Page: p.1 |
| Exfoliative dermatitis | Disc. AE | 250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Fingernail onychomycosis|Toenail onychomycosis Sources: Page: p.1 |
| Liver failure | Disc. AE | 250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Fingernail onychomycosis|Toenail onychomycosis Sources: Page: p.1 |
| Smell alteration | Disc. AE | 250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Fingernail onychomycosis|Toenail onychomycosis Sources: Page: p.1 |
| Stevens-Johnson syndrome | Disc. AE | 250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Fingernail onychomycosis|Toenail onychomycosis Sources: Page: p.1 |
| Toxic epidermal necrolysis | Disc. AE | 250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Fingernail onychomycosis|Toenail onychomycosis Sources: Page: p.1 |
| Neutropenia | severe Disc. AE |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Fingernail onychomycosis|Toenail onychomycosis Sources: Page: p.1 |
| Taste disturbance | severe Disc. AE |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Fingernail onychomycosis|Toenail onychomycosis Sources: Page: p.1 |
| Hemolytic uremic syndrome | Disc. AE | 250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: p.3 |
unhealthy Health Status: unhealthy Condition: Fingernail onychomycosis|Toenail onychomycosis Sources: Page: p.3 |
| Lupus erythematosus | Disc. AE | 250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: p.3 |
unhealthy Health Status: unhealthy Condition: Fingernail onychomycosis|Toenail onychomycosis Sources: Page: p.3 |
| Thrombotic microangiopathy | Disc. AE | 250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: p.3 |
unhealthy Health Status: unhealthy Condition: Fingernail onychomycosis|Toenail onychomycosis Sources: Page: p.3 |
| Thrombotic thrombocytopenic purpura | Disc. AE | 250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: p.3 |
unhealthy Health Status: unhealthy Condition: Fingernail onychomycosis|Toenail onychomycosis Sources: Page: p.3 |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Page: - |
yes [Ki 0.03 uM] | yes (co-administration study) Comment: In studies in healthy subjects characterized as extensive metabolizers of dextromethorphan (antitussive drug and CYP2D6 probe substrate), terbinafine increases the dextromethorphan/ dextrorphan metabolite ratio in urine by 16- to 97-fold on average Page: - |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | yes (co-administration study) Comment: Coadministration of a single dose of fluconazole (100 mg) with a single dose of terbinafine resulted in a 52% and 69% increase in terbinafine Cmax and AUC, respectively. Fluconazole is an inhibitor of CYP2C9 and CYP3A enzymes. Based on this finding, it is likely that other inhibitors of both CYP2C9 and CYP3A4 (e.g., ketoconazole, amiodarone) may also lead to a substantial increase in the systemic exposure (Cmax and AUC) of terbinafine when concomitantly administered. Page: - |
||
| yes | yes (co-administration study) Comment: Coadministration of a single dose of fluconazole (100 mg) with a single dose of terbinafine resulted in a 52% and 69% increase in terbinafine Cmax and AUC, respectively. Fluconazole is an inhibitor of CYP2C9 and CYP3A enzymes. Based on this finding, it is likely that other inhibitors of both CYP2C9 and CYP3A4 (e.g., ketoconazole, amiodarone) may also lead to a substantial increase in the systemic exposure (Cmax and AUC) of terbinafine when concomitantly administered. Page: 5.0 |
Tox targets
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Page: - |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Antifungal activity of the allylamine derivative terbinafine in vitro. | 1987 Sep |
|
| Terbinafine: mode of action and properties of the squalene epoxidase inhibition. | 1992 Feb |
|
| Terbinafine-induced prolonged cholestasis with reduction of interlobular bile ducts. | 1997 Jul |
|
| Comparative study of antifungal activity of sertaconazole, terbinafine, and bifonazole against clinical isolates of Candida spp., Cryptococcus neoformans and dermatophytes. | 1997 Nov-Dec |
|
| Safety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patients. | 1997 Oct |
|
| In vitro activities of terbinafine against cutaneous isolates of Candida albicans and other pathogenic yeasts. | 1998 May |
|
| Terbinafine. An update of its use in superficial mycoses. | 1999 Jul |
|
| An evaluation of the in vitro activity of terbinafine. | 2000 Apr |
|
| Inhibitors of sterol biosynthesis and amphotericin B reduce the viability of pneumocystis carinii f. sp. carinii. | 2000 Jun |
|
| Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans. | 2000 Sep |
|
| In vitro activities of terbinafine against Aspergillus species in comparison with those of itraconazole and amphotericin B. | 2001 Jun |
|
| Terbinafine: a review of its use in onychomycosis in adults. | 2003 |
|
| Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei. | 2003 Mar |
|
| [Colestasic toxic hepatitis caused by terbinafine: case report]. | 2004 Oct-Dec |
|
| Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality. | 2005 Dec |
|
| Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
| Terbinafine inhibits endothelial cell migration through suppression of the Rho-mediated pathway. | 2006 Dec |
|
| Comparable efficacy and safety of various topical formulations of terbinafine in tinea pedis irrespective of the treatment regimen: results of a meta-analysis. | 2007 |
|
| Terbinafine-induced hepatic failure requiring liver transplantation. | 2007 Jan |
|
| Terbinafine-induced acute autoimmune hepatitis in the setting of hepatitis B virus infection. | 2007 May |
|
| N- and S-alpha-l-arabinopyranosyl[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles. First synthesis and biological evaluation. | 2007 Sep |
|
| Terbinafine-induced acute generalized exanthematous pustulosis. | 2008 Apr |
|
| Synthesis of new N-phenylpyrazole derivatives with potent antimicrobial activity. | 2008 Apr 15 |
|
| Fungicide activity of 5-(4-chlorobenzylidene)-(Z)-2-dimethylamino-1,3-thiazol-4-one against Cryptococcus neoformans. | 2010 Jan |
|
| Efficient synthesis of novel 1,2,4-triazole fused acyclic and 21-28 membered macrocyclic and/or lariat macrocyclic oxaazathia crown compounds with potential antimicrobial activity. | 2010 Nov |
|
| Development of a highly sensitive cytotoxicity assay system for CYP3A4-mediated metabolic activation. | 2011 Aug |
|
| FDA-approved drugs and other compounds tested as inhibitors of human glutathione transferase P1-1. | 2013 Sep 5 |
|
| Genomic models of short-term exposure accurately predict long-term chemical carcinogenicity and identify putative mechanisms of action. | 2014 |
|
| Synthesis, antifungal activities and molecular docking studies of novel 2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl dithiocarbamates. | 2014 Mar 3 |
|
| Arachidonic acid affects biofilm formation and PGE2 level in Candida albicans and non-albicans species in presence of subinhibitory concentration of fluconazole and terbinafine. | 2014 May-Jun |
|
| Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. | 2015 May 18 |
|
| A metoprolol-terbinafine combination induced bradycardia. | 2015 Sep |
Patents
Sample Use Guides
Prior to administering, evaluate patients for evidence of chronic or active
liver disease.
Fingernail onychomycosis: One 250 mg tablet, once daily for 6 weeks.
Toenail onychomycosis: One 250 mg tablet, once daily for 12 weeks.
Route of Administration:
Oral
TRB (Terbinafine) were diluted 100-fold in dimethyl sulfoxide to obtain stock solutions that were kept at -20ºC. The antifungals were diluted in RPMI-1640 medium (Sigma Chemical Co, Missouri, USA) at pH 7.0 buffered with 0.16 M morpholinepropanesulfonic acid to obtain final concentrations ranging from 0.03-16 μg/mL for TRB. The diluted antifungal suspensions were then added to 96-well microtitre trays. Next, each fungal suspension was inoculated into the appropriate well at final concentrations ranging from 0.5 x 10^3-2.5 x 10^3 CFU/mL. The minimum inhibitory concentration (MIC) of each antifungal was determined by spectrophotometric reading at 492 nm following incubation at 35ºC for 72 h.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
176168-78-8
Created by
admin on Sat Dec 16 09:24:28 GMT 2023 , Edited by admin on Sat Dec 16 09:24:28 GMT 2023
|
PRIMARY | |||
|
1643532
Created by
admin on Sat Dec 16 09:24:28 GMT 2023 , Edited by admin on Sat Dec 16 09:24:28 GMT 2023
|
PRIMARY | |||
|
71752365
Created by
admin on Sat Dec 16 09:24:28 GMT 2023 , Edited by admin on Sat Dec 16 09:24:28 GMT 2023
|
PRIMARY | |||
|
2H771UZ786
Created by
admin on Sat Dec 16 09:24:28 GMT 2023 , Edited by admin on Sat Dec 16 09:24:28 GMT 2023
|
PRIMARY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
